Background: The recent advances in precision oncology for lung cancer treatment has focused attention on the importance of obtaining appropriate specimens for tissue diagnosis as well as comprehensive molecular profiling. CT scan-guided biopsies and bronchoscopy are currently the main procedures employed for tissue sampling. However, growing evidence suggests that ultrasound-guided biopsies may represent an effective as well as safe approach in this diagnostic area. This study explores the safety and the diagnostic yield for cancer molecular profiling in ultrasound-guided percutaneous lung lesion biopsies (US-PLLB). Methods: One hundred consecutive patients with suspected lung cancer, between January 2021 and May 2024, who had ultrasound-guided lung biopsies have been retrospectively analyzed. Molecular profiling was conducted with next-generation sequencing Genexus using Oncomine precision assay or polymerase chain reaction according to specimen quality. Qualitative immunohistochemical assay of programmed death ligand 1 (PD-L1) expression was evaluated by the Dako PD-L1 immunohistochemistry 22C3 pharmDx assay. The co-primary endpoints were the molecular diagnostic yield and the safety profile of US-guided lung biopsies. Results: From January 2021 to May 2024, 100 US-guided lung biopsies were carried out and 95 were considered for inclusion in the study. US-PLLB provided informative tissue for a histological evaluation in 93 of 95 patients with an overall diagnostic accuracy of 96.84% [Sensitivity: 92.63%; Specificity: 96.84%; PPV: 100%; NPV: 100%]. Sixty-Six patients were diagnosed with NSCLC (69.47%) and were considered for molecular diagnostic yield evaluation and PD-L1 testing. Four patients had malignant lymphoid lesions. US-PLLB was not adequate to achieve a final diagnosis in three patients (3.16%). Complete molecular profiling and PD-L1 evaluation were achieved in all patients with adenocarcinoma (molecular diagnostic yield: 100%). PD-L1 evaluation was achieved in 28 of 29 patients (96.55%) with either SCC or NOS lung cancer. The overall complication rate was 9.47% (n = 9). Six patients (6.31%) developed pneumothorax, while three patients (3.16%) suffered mild haemoptysis without desaturation. Conclusions: According to our findings, US-guided lung biopsy is a safe, minimally invasive procedure in patients with suspected lung malignancies, providing an excellent diagnostic yield for both comprehensive molecular profiling and PD-L1 testing. In addition, our results suggest that US-guided biopsy may also be an effective diagnostic approach in patients with suspected lung lymphoma.

Background: Several studies have reported the association between malnutrition risk and survival outcomes in surgically treated lung cancer patients; in contrast, limited data are available on patients undergoing medical therapies. The aim of this study was to evaluate malnutrition risk (using the CONUT score) and its relationships with treatment response and survival in patients with an advanced stage of non-small cell lung cancer (NSCLC). Methods: We retrospectively evaluated 109 patients with a diagnosis of locally advanced and advanced NSCLC. Patients were assessed at baseline (before any therapy), after four cycles of therapy, and during a follow-up period of 4 years. Results: Thirty-two (29.4%) NSCLC patients had a CONUT score ≥ 2. Patients with a higher CONUT score were more likely to have brain metastases while patients with a CONUT score < 2 had a significantly better response to therapy in terms of partial response/stable disease. In addition, The Kaplan–Meier curves revealed a significantly worse prognosis for the high CONUT than the low CONUT group regarding both OS and PFS. Cox regression analysis indicated that the CONUT score (≥2) was as a significant determinant of OS and PFS in the patients studied even after considering other possible predictors. Conclusion: This study suggests that malnutrition risk assessment with CONUT score may be valuable in the prognosis assessment of advanced-stage NSCLC patients.

Background: A tracheoesophageal fistula (TEF) represents a condition characterized by abnormal communication between the gastrointestinal tract and the airways. Although the current gold-standard treatment is surgery, pre-existing clinical conditions may represent contraindications. We therefore propose a bronchoscopic approach through rigid bronchoscopy without tracheostomy for total repair in patients suffering from benign tracheoesophageal fistulas. Methods: Fistula suture through rigid bronchoscopy with either absorbable (Vycryl 3.0, Ethicon, Inc.) or non-absorbable (Prolene, Ethicon US, LLC. 2022.) sutures was performed using a long needle holder as an alternative resolutive procedure to surgery. From 2015 to 2022, we retrospectively reviewed 10 consecutive patients affected by TEFs in our Endoscopic Unit at San Camillo-Forlanini Hospital (Rome, Italy) who underwent this bronchoscopic procedure. The coprimary outcomes were the proportion of fistulas successfully treated with the innovative treatment proposed and the rate of procedure-related complications. Results: The complete healing of the fistula was achieved in nine of the ten patients after 1 year. Follow-up with flexible bronchoscopy was scheduled and carried out at 1, 3, and 12 months following rigid bronchoscopy. Overall, seventeen endoscopic repair procedures were performed. Five of these patients required more than one endoscopic treatment to reach complete fistula closure. Fistula closure was not achieved post-procedure in one patient. No complications during procedures or in the follow-up period were reported. Conclusions: Despite the small cohort, our preliminary study has demonstrated that the endoscopic approach through rigid bronchoscopy, without tracheostomy, represents a safe and satisfactory alternative for patients affected by TEFs who are not suitable for surgery.